Results 71 to 80 of about 271,655 (296)

Biology of Hodgkin's lymphoma

open access: yesAnnals of Oncology, 2002
Significant progress has been made in recent years in our understanding of the cellular origin of Hodgkin and Reed-Sternberg (HRS) cells in Hodgkin's lymphoma (HL). It is now clear that in most instances HRS cells represent clonal populations of transformed germinal centre (GC) B cells.
R, Küppers   +4 more
openaire   +2 more sources

Distinct Molecular Pathways Supporting Sjögren Disease Clusters and Disease Progression

open access: yesArthritis &Rheumatology, EarlyView.
Objective Sjögren disease (SjD) is a heterogeneous autoimmune disease. We aimed to investigate blood transcriptomic signatures and disease progression among three recently defined clusters of patients with SjD: (1) B cell active disease with low symptom burden (BALS), (2) high systemic activity (HSA), and (3) low systemic activity with high symptom ...
Sacha E. Silva‐Saffar   +6 more
wiley   +1 more source

Peripheral Blood DNA Methylation Changes Precede Lymphoma Diagnosis in Primary Sjögren's Disease

open access: yesArthritis &Rheumatology, EarlyView.
Objective Primary Sjögren's disease (SjD) is a systemic autoimmune disease associated with an increased risk of lymphoma. The molecular mechanisms underlying lymphomagenesis remain poorly understood, and sensitive biomarkers for early identification of patients at high risk of developing lymphoma are lacking.
Hanna Lidberg   +2 more
wiley   +1 more source

Comparative global burden analysis of lymphoma subtypes: a statistical evaluation of severity across global regions

open access: yesFrontiers in Public Health
IntroductionVarious subtypes of lymphoma, including Hodgkin lymphoma, non-Hodgkin lymphoma, and Burkitt lymphoma, impose a significant global health burden.
Yu Liang   +7 more
doaj   +1 more source

Relapsed and Refractory Hodgkin Lymphoma

open access: yes, 2014
High-dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) is the standard treatment for patients with relapsed or refractory Hodgkin lymphoma (HL).
Moskowitz, Craig   +3 more
core   +1 more source

Classical Hodgkin lymphoma [PDF]

open access: yes, 2017
Lymphocyte-rich classical Hodgkin lymphoma accounts for a small fraction of all Hodgkin lymphomas. Lymphocyte-rich classical Hodgkin lymphoma is a rare variant of classical Hodgkin lymphoma which resembles nodular lymphocyte predominance Hodgkin lymphoma,
Gloghini, Annunziata, Carbone, Antonino
core   +1 more source

Risk of Cancer According to Duration of Targeted Therapy Exposure in Spondyloarthritis: A Nationwide Cohort Study From the French Health Insurance Database

open access: yesArthritis &Rheumatology, EarlyView.
Objective To assess the association between duration of targeted therapy exposure and cancer risk in patients with spondyloarthritis (SpA), including those with psoriatic arthritis, axial SpA, and other subtypes. Methods This nationwide cohort study used the French health insurance database to identify adults with SpA initiating a targeted therapy ...
Karine Tankovic   +7 more
wiley   +1 more source

Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma [PDF]

open access: yes, 2011
PURPOSE: This analysis from an observational study of clinical practice describes the impact of febrile neutropenia (FN) on chemotherapy delivery and hospitalizations.
Rossi, F G   +46 more
core   +1 more source

Single‐cell RNA sequencing of peripheral blood defines two immunological subtypes of Sjögren's disease distinguished by anti‐SSA antibodies and aberrant B cell populations

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives Sjögren's disease (SjD) is a heterogeneous autoimmune disorder characterized by substantial clinical and molecular diversity. This heterogeneity raises key questions regarding the existence of distinct pathogenic mechanisms underlying disease subtypes.
Geoffrey Urbanski   +15 more
wiley   +1 more source

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia—A comprehensive review

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy